These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 20392512

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
    García-Monzón C, Lo Iacono O, Mayoral R, González-Rodríguez A, Miquilena-Colina ME, Lozano-Rodríguez T, García-Pozo L, Vargas-Castrillón J, Casado M, Boscá L, Valverde AM, Martín-Sanz P.
    J Hepatol; 2011 Jan; 54(1):142-52. PubMed ID: 20888662
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?
    Gambino R, Cassader M, Pagano G, Durazzo M, Musso G.
    Hepatology; 2007 May; 45(5):1097-107. PubMed ID: 17464986
    [Abstract] [Full Text] [Related]

  • 9. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN, Tao RY, Tian JY, Liu GT, Ye F.
    Life Sci; 2008 May 07; 82(19-20):983-90. PubMed ID: 18417155
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice.
    Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D.
    Hepatology; 2003 Jul 07; 38(1):133-40. PubMed ID: 12829995
    [Abstract] [Full Text] [Related]

  • 11. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakanuma Y, Kaneko S.
    Gastroenterology; 2007 Jan 07; 132(1):282-93. PubMed ID: 17241878
    [Abstract] [Full Text] [Related]

  • 12. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE.
    Am J Gastroenterol; 2008 Jun 07; 103(6):1372-9. PubMed ID: 18510618
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.
    Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S.
    Hepatology; 2007 Nov 07; 46(5):1392-403. PubMed ID: 17929294
    [Abstract] [Full Text] [Related]

  • 15. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
    Matsunami T, Sato Y, Ariga S, Sato T, Shimomura T, Kashimura H, Hasegawa Y, Yukawa M.
    Metabolism; 2011 Jun 07; 60(6):805-14. PubMed ID: 20846698
    [Abstract] [Full Text] [Related]

  • 16. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model.
    Zago V, Lucero D, Macri EV, Cacciagiú L, Gamba CA, Miksztowicz V, Berg G, Wikinski R, Friedman S, Schreier L.
    Ann Nutr Metab; 2010 Jun 07; 56(3):198-206. PubMed ID: 20203480
    [Abstract] [Full Text] [Related]

  • 17. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
    Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, Kirikoshi H, Inamori M, Kubota K, Saito S, Mizoue T, Masaki N, Nagashima Y, Terauchi Y, Nakajima A.
    J Hepatol; 2009 Sep 07; 51(3):548-56. PubMed ID: 19596472
    [Abstract] [Full Text] [Related]

  • 18. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T.
    Liver Int; 2006 Jun 07; 26(5):613-20. PubMed ID: 16762007
    [Abstract] [Full Text] [Related]

  • 19. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?
    Ariz U, Mato JM, Lu SC, Martínez Chantar ML.
    Methods Mol Biol; 2010 Jun 07; 593():109-36. PubMed ID: 19957147
    [Abstract] [Full Text] [Related]

  • 20. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.
    VerHague MA, Cheng D, Weinberg RB, Shelness GS.
    Arterioscler Thromb Vasc Biol; 2013 Nov 07; 33(11):2501-8. PubMed ID: 24030551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.